Prime Medicine, Inc. (PRME) stock
PRMENasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$3.84−0.35 (-8.35%)
Close on Nov 17, 2026Market cap $696.49MP/E –Yield –
Earnings
Prime Medicine's quarterly results as reported in its earnings releases, with the company's own outlook. Hover a number to see the sentence it came from.
Next report
Mar 2, 2027
Q4 FY2026 · estimated, before the open
Revenue, Q2 FY2025
$1.12M
EPS, Q2 FY2025
-$0.41
-$0.46 a year earlier
Latest guidance
None
No outlook given in releases
Quarterly results
Revenue and earnings per share from each of Prime Medicine's earnings releases, newest first
| Quarter | Reported | Revenue | YoY | EPS | Source |
|---|---|---|---|---|---|
| Q4 FY2026ended Dec 31, 2026 | Mar 2, 2027Expected | – | – | – | – |
| Q3 FY2026ended Sep 30, 2026 | Nov 12, 2026after the close | – | – | – | Release |
| Q2 FY2026ended Jun 30, 2026 | Aug 6, 2026before the open | – | – | – | Release |
| Q1 FY2026ended Mar 31, 2026 | May 7, 2026before the open | – | – | – | Release |
| Q4 FY2025ended Dec 31, 2025 | Mar 3, 2026before the open | – | – | – | Release |
| Q3 FY2025ended Sep 30, 2025 | Nov 7, 2025before the open | – | – | – | Release |
| Q2 FY2025ended Jun 30, 2025 | Aug 7, 2025before the open | $1.12M | – | -$0.41 | Release |
| Q1 FY2025ended Mar 31, 2025 | May 8, 2025before the open | – | – | – | Release |
| Q4 FY2024ended Dec 31, 2024 | Feb 28, 2025before the open | – | – | – | Release |
| Q3 FY2024ended Sep 30, 2024 | Nov 12, 2024during market hours | – | – | – | Release |
| Q2 FY2024ended Jun 30, 2024 | Aug 8, 2024before the open | – | – | -$0.46 | Release |
| Q1 FY2024ended Mar 31, 2024 | May 10, 2024before the open | $591.00K | – | -$0.44 | Release |
| Q4 FY2023ended Dec 31, 2023 | Mar 1, 2024before the open | – | – | – | Release |
| Q3 FY2023ended Sep 30, 2023 | Nov 3, 2023during market hours | – | – | -$0.55 | Release |
| Q2 FY2023ended Jun 30, 2023 | Aug 7, 2023during market hours | – | – | -$0.47 | Release |
| Q1 FY2023ended Mar 31, 2023 | May 11, 2023before the open | – | – | -$0.44 | Release |
| Q4 FY2022ended Dec 31, 2022 | Mar 9, 2023before the open | – | – | -$0.56 | Release |
Figures as first announced; later restatements appear under Financials. Expected dates are estimated from the company's past reporting pattern.
Guidance
Prime Medicine has not given guidance in its releases
Many companies give their outlook only on the conference call or not at all. When Prime Medicine puts a forecast in an earnings release, it is listed here with the exact sentence.
Press releases
Releases Prime Medicine filed with the SEC as exhibits to Form 8-K or 6-K
- Results
- Results
- Results
- Results
- Results
- Results
- Update
- Results
- Update
- Results
- Results
- Update
- Update
- Update
- Results
See a number that looks wrong?